Diazoxide

([(3S)‐6‐({2′,6′‐dimethyl‐4′‐[3‐(methylsulfonyl)propoxy]biphenyl‐3‐yl}methoxy)‐2,3‐dihydro‐1‐benzofuran‐3‐yl]acetic acid hemihydrate) was synthesized at Takeda Pharmaceutical Company (Osaka, Japan). Diazoxide, KCl, and glimepiride were purchased from Wako Pure Chemical Industries (Osaka, Japan). Sterile D‐(+)‐glucose solution (45% in water), γ‐linolenic acid (γ‐LA), and (S)‐(‐)‐Bay K8644 were purchased from Sigma‐Aldrich (St. Louis, MO). D‐myo‐inositol 1,3,5‐trisphosphate hexakisacetoxymethyl ester, 2,4,6‐tri‐O‐butyryl (Bt₃IP₃), a cell‐permeable derivative of D‐myo‐inositol 1,3,5‐trisphosphate, was purchased from Merck Millipore (Tokyo, Japan). A cell‐permeable analog of DAG, 1‐oleoyl‐2‐acetyl‐sn‐glycerol (OAG), was purchased from Cayman Chemical (Ann Arbor, MI). Nifedipine was purchased from MP Biomedicals (Tokyo, Japan). Krebs‐Ringer‐bicarbonate‐HEPES (KRBH) buffer (116 mmol/L NaCl, 4.7 mmol/L KCl, 1.17 mmol/L KH₂PO₄, 1.17 mmol/L MgSO₄, 25 mmol/L NaHCO₃, 2.52 mmol/L CaCl₂, and 24 mmol/L HEPES (pH 7.4)) containing 0.2% bovine serum albumin (BSA) was freshly prepared before each experiment. Fura‐2 acetoxymethyl ester was purchased from Dojindo Laboratories (Kumamoto, Japan).

The Prestwick Chemical Library was purchased from PerkinElmer. Dimethyl sulfoxide (DMSO), 2-deoxy-d-glucose (2-DG), diazoxide, cyclosporin A (CsA), N-acetyl cysteine (NAC), IPA-3, bifonazole, verapamil, tunicamycin, and thapsigargin were purchased from Wako. Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), deferoxamine mesylate, importazole, ivermectin, and oligomycin A were purchased from Sigma-Aldrich. Mito-TEMPO was purchased from Enzo Life Sciences. Compound 968 was purchased from Calbiochem. Dexrazoxane was purchased from TCI Chemicals. Cariporide was purchased from Cayman Chemical. Nifuroxazide was purchased from MP Biomedicals. 2-Methylthioadenosine triphosphate (2-meSATP) was purchased from Tocris. Azoramide was purchased from Ark Pharm, Inc.